Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections (C-Section)
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section
Sponsor: Pacira Pharmaceuticals, Inc
Listed as NCT03176459, this PHASE4 trial focuses on C-Section and Pain Management and remains completed. Sponsored by Pacira Pharmaceuticals, Inc, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE4
-
May 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .